Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Board Appointment Confirmation

28th Apr 2025 07:00

RNS Number : 3205G
SkinBioTherapeutics PLC
28 April 2025
 

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Board Appointment Confirmation

 

28 April 2025 - Further to the Group's announcement on 24 April 2025, the Board of Directors of SkinBioTherapeutics, (AIM: SBTX), a life science company focused on skin health, now confirms the appointment of Simon Hewitson as an Executive Director on the Board and Chief Operating Officer of the Group, with immediate effect.

 

The following information is disclosed pursuant to rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies:

 

Full name:

Simon Jonathan Hewitson

Age:

49

Shareholding in SkinBioTherapeutics:

None

Current directorships held:

None

Directorships held in the previous 5 years:

Northumbrian Ice Cream Company LimitedPolar Krush Group Limited

 

-Ends-

For more information please contact:

 

SkinBioTherapeutics plc

Martin Hunt, Chair

Stuart J. Ashman, CEO​

 

+44 (0) 191 495 7325

 

Cavendish Capital Markets Limited

(Nominated Adviser & Broker)

Giles Balleny, Dan Hodkinson (Corporate Finance)

Charlie Combe (Broking)

Dale Bellis (Sales)​

+44 (0) 20 7220 0500

 

Vigo Consulting (financial press)

Rozi Morris

+44 (0) 20 7390 0230

[email protected]

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements to modulate the immune system by harnessing the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the SkinBiotix active ingredient, Zenakine™ was launched in April 2025. The Group's first in-house product, AxisBiotix-Ps™, is a food supplement to address the symptoms of mild to moderate psoriasis.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products. 

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAPLSAEFSEFA

Related Shares:

Skinbiotherap.
FTSE 100 Latest
Value8,721.27
Change-4.74